CN110833595A - Traditional Chinese medicine composition for treating gout and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating gout and preparation method thereof Download PDFInfo
- Publication number
- CN110833595A CN110833595A CN201810957243.2A CN201810957243A CN110833595A CN 110833595 A CN110833595 A CN 110833595A CN 201810957243 A CN201810957243 A CN 201810957243A CN 110833595 A CN110833595 A CN 110833595A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- parts
- chinese medicine
- gout
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 79
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 241000233779 Cyclocarya paliurus Species 0.000 claims abstract description 31
- 240000008042 Zea mays Species 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 241001598107 Imperata Species 0.000 claims abstract description 15
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 15
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 15
- 235000005822 corn Nutrition 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims abstract description 8
- 238000004806 packaging method and process Methods 0.000 claims abstract description 8
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 5
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 5
- 238000010298 pulverizing process Methods 0.000 claims abstract description 3
- 238000007873 sieving Methods 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 27
- 230000001154 acute effect Effects 0.000 abstract description 15
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 8
- 230000008961 swelling Effects 0.000 abstract description 6
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 229960002708 antigout preparations Drugs 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 208000002193 Pain Diseases 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 30
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 22
- 229940116269 uric acid Drugs 0.000 description 22
- 241000700159 Rattus Species 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 230000008569 process Effects 0.000 description 10
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 9
- 230000029142 excretion Effects 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 201000001431 Hyperuricemia Diseases 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 102000003777 Interleukin-1 beta Human genes 0.000 description 8
- 108090000193 Interleukin-1 beta Proteins 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 7
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 206010023232 Joint swelling Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 235000007244 Zea mays Nutrition 0.000 description 5
- 229940089639 cornsilk Drugs 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000010977 jade Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000001231 zea mays silk Substances 0.000 description 5
- 210000000544 articulatio talocruralis Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 229940126673 western medicines Drugs 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- MCTQNEBFZMBRSQ-GEEYTBSJSA-N Chrysoidine Chemical group Cl.NC1=CC(N)=CC=C1\N=N\C1=CC=CC=C1 MCTQNEBFZMBRSQ-GEEYTBSJSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- -1 DPPH free radical Chemical class 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 102100023426 Kinesin-like protein KIF2A Human genes 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241001528187 Paliurus Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- RDFLLVCQYHQOBU-ZOTFFYTFSA-O cyanin Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=[O+]C1=CC(O)=C2)C=3C=C(O)C(O)=CC=3)=CC1=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RDFLLVCQYHQOBU-ZOTFFYTFSA-O 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 108010078530 urate transporter Proteins 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating gout and a preparation method thereof, belonging to the field of traditional Chinese medicines; the gout traditional Chinese medicine composition comprises, by weight, 40-80 parts of cyclocarya paliurus, 10-40 parts of corn stigma, 5-30 parts of kudzu root and 5-30 parts of lalang grass rhizome. The composition is prepared by mixing the raw materials according to a certain proportion, decocting, concentrating, drying, pulverizing, sieving, and finally packaging. The anti-gout traditional Chinese medicine composition provided by the invention is simple in formula and simple and convenient in preparation process, and can well retain active ingredients of the composition. The effect of the prescription for treating gout is better than the curative effect of a single traditional Chinese medicine and any two-traditional Chinese medicine combination and three-traditional Chinese medicine combination of the prescription, the synergistic effect of the single traditional Chinese medicine in the prescription can be exerted to improve the clinical symptoms of acute gout attack joint redness and swelling and pain and slow down the attack of complications of patients with chronic gout, and the prescription has the characteristics of convenience in taking, safety and no toxic or side effect.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating gout and a preparation method thereof.
Background
Gout is caused by hyperuricemia (serum uric acid concentration > 420umol/L) causing crystallization of sodium urate, deposition on joints and cartilage tissue around joints, causing accumulation of neutrophils and joint synovial cells to The sodium urate crystallization sites, release of inflammatory cytokines (IL-1 β, TNF- α), and severe inflammatory response caused by chemokines [ Miguel A. Martillo, LamaNazzal, Dariab. Cfitenden The crystallization of monocondium urate. Current Rheumatomatoutoxy Reports, 2014, 16 (2): 400 ].
Hyperuricemia is the biochemical basis for gout development. The uric acid content is increased due to the excessive production of uric acid in the body or the reduction of uric acid excretion. Among them, approximately 90% of hyperuricemia is caused by decreased uric acid excretion due to renal uric acid excretion disorder, and the rest is hyperuricemia caused by increased uric acid production due to metabolic disorder of purine substances in the body or excessive purine-rich food intake. [ Ichida Kimiyoshi, Matsuo Hirotaka, Takada Tappei, et al, classified extra-crude mutation is a common house of hyperuricemia. Nature Communications, 2012, 3: 764].
The sodium urate crystal can further activate NLRP3 inflammasome through generating active oxygen, promote the organism to secrete inflammatory cell factors, and further initiate gout.
The course of gout can be divided into asymptomatic hyperuricemia, an acute gout attack, an intermittent gout attack, and a chronic tophus lesion. In addition to the onset of gout causing inflammatory symptoms such as red swelling and pain, complications such as hypertension, hyperlipidemia, hyperglycemia, and cardiovascular diseases are also caused in the late stage of gout [ yanyanyanyan Zhu, bhavirkj Pandya, hyonkchoi. comorbidities of goule and hypemricemia in the US general publication: NHANES 2007-2008.American Journal of Medicine, 2012, 125 (7): 679-687].
Currently, gout treatment is mainly based on controlling joint inflammation caused by acute gout attack and reducing body uric acid [ Khanna Dinesh, PujaP Khanna, john d Fitzgerald et, al.2012 American college of Rheumatology guidelines for management of gout.part 2: thermal and innovative mapping of the amino acids of: 1447-61]. Colchicine, non-steroidal anti-inflammatory drugs and glucocorticoids are mainly used in controlling joint inflammation. Short-term administration of glucocorticoids may be an option when patients develop tolerance to colchicine and non-steroidal anti-inflammatory drugs and severe adverse reactions. The medicine is used for inhibiting excessive production of uric acid and promoting excretion of uric acid in kidney in reducing uric acid in body. In the aspect of reducing the production of uric acid, allopurinol and febuxostat inhibit the production of uric acid in the body by using a key enzyme xanthine oxidase in the purine metabolic process of the body; in promoting uric acid excretion, it mainly acts on urate transporters to promote uric acid renal excretion, such as benzbromarone and probenecid. However, the above drugs have various degrees of adverse reactions. For example, colchicine can cause gastrointestinal reactions such as nausea, vomiting, abdominal pain and bloating, nonsteroidal anti-inflammatory drugs can cause gastrointestinal bleeding, gastrointestinal perforation, allopurinol can cause cutaneous allergic reactions and impairment of hepatic renal function [ Khanna index, PujaPKhanna, john d Fitzgerald, et, al.2012 American College of rhematotoglypeptides for management of gout.part 2: the mpy and anti-natnammatoxyphenylaxis of acid route and its Research, arthritis care Research, 2012, 64 (10): 1447. therefore, the development of a new medicament for treating gout, which is safe and has small side effect and is suitable for long-term administration by patients, is particularly important.
The traditional Chinese medicine is a natural product and is rich in various components, so that the traditional Chinese medicine has the effects of multiple components, multiple targets and overall synergy in the process of treating diseases. In the process of treating diseases, compared with western medicines, the traditional Chinese medicine has the advantages of small side effect, reduction of complications and low treatment cost, so that the traditional Chinese medicine is paid more and more attention in the development process of new medicines.
Aiming at a plurality of adverse reactions existing in the current western medicines for clinically treating gout, the traditional Chinese medicine is a natural medicine, and has the advantages of multiple components and multiple targets, safety and no toxic or side effect compared with the western medicines in the process of treating diseases because the traditional Chinese medicine is rich in a plurality of natural components.
Disclosure of Invention
The invention aims to solve the technical problems that western medicines have high side effects, gout is easy to relapse after stopping medicine and complications caused by gout exist in the existing gout treatment process.
In order to solve the technical problems, the invention discloses the following technical scheme:
a traditional Chinese medicine composition for treating gout comprises the following raw materials in parts by weight:
40-80 parts of cyclocarya paliurus, 10-40 parts of corn stigma, 5-30 parts of kudzu root and 5-30 parts of lalang grass rhizome.
Preferably, the traditional Chinese medicine composition for treating gout comprises the following raw materials in parts by weight: 80 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of rhizoma imperatae.
Meanwhile, the invention also preferably discloses a preparation method of the traditional Chinese medicine composition for treating gout, which comprises the following steps: mixing the raw materials at a certain ratio, decocting, concentrating, drying, pulverizing, sieving and packaging. The method comprises the following specific steps:
a) adding 8-10 times of distilled water according to the total mass of the mixed raw materials.
b) Decocting the mixture at 80-100 deg.C for 1-2 hr, and continuously decocting for 2-3 times.
c) Concentrating the obtained decoction under reduced pressure to obtain soft extract with relative density of 1.20-1.30.
d) Drying the obtained thick extract at 60-80 deg.C to obtain dry powder.
e) Packaging the dry powder.
Cyclocarya paliurus (Batal) Iljinsk is a tree plant of Cyclocarya paliurus of Juglandaceae, and researches report that the extract of Cyclocarya paliurus leaves has pharmacological effects of reducing blood sugar, reducing blood fat, resisting oxidation, resisting inflammation and the like. Cyclocarya paliurus aqueous extract can obviously reduce malondialdehyde level in blood serum of diabetic rats and obviously increase the levels of SOD (superoxide dismutase) and GSH-Px (glutathione peroxidase) [ Qingqing wang, Cuihua Jiang, Shengzuo Fang, et, al. 1119-1127]. The polysaccharide component can obviously eliminate DPPH free radical [ Jianhua Xie, Mingyong Xie, shading Nie, Shen, et, al. isolation, chemical composition and antioxidant activities of a water-soluble polysaccharide from cyclic supplement (Batal.) Iljinskaja. food Chem, 2010, 119, 1626-. Cyclocarya paliurus alcohol extract can improve insulin resistance by anti-inflammation [ Cuihua Jiang, Nan Yao, Qingqing Wang, et, al. Cyclocaraya paliurus palaitus extract models adoptorienxexpression and improved insulin sensitivity by inhibition of inflammation information. journal of Ethnopharmacology, 2014, 153, 344. Anoplochia 351 ].
The corn silk [ Stigmamaydis ] is a dry style and stigma of a gramineous crop corn, and has the effects of inducing diuresis to alleviate edema, clearing heat, reducing blood pressure, calming liver and benefiting gallbladder, and the like, modern pharmacological studies show that the corn silk [ Stigmamaydis ] has the effects of reducing blood sugar, resisting gout, resisting cancer and inhibiting bacteria, and the like, flavonoid components of the corn silk can obviously reduce the ankle joint swelling of rats caused by sodium urate, the levels of inflammatory factors IL-1 β, TNF- α and MCP-1 in serum, and improve the pathological characteristics of synovial tissues of rats [ forest greeting, Dongjinxiang, and the like ], the influence of a corn silk flavone extract on gouty arthritis rats, modern food science and technology, 2015, 31 (4): 13-17], the corn silk water extract can reduce blood sugar value by increasing insulin level and repairing damaged β -cells, and the like.
Pueraria lobata (Willd) Ohwi is dried root of Pueraria lobata (Willd) Ohwi) of Leguminosae, and has effects of relieving exterior syndrome, clearing away heat, promoting fluid production, quenching thirst, invigorating yang and relieving diarrhea. Puerarin is the main drug effect component of radix Puerariae, and research shows that puerarin has effects of resisting inflammation and treating gout. In vitro experimental studies show that puerarin can inhibit the activity of xanthine oxidase, reduce the generation of uric acid, and treat gout [ prosperity, screening of traditional Chinese medicine xanthine oxidase inhibitor and inhibition kinetics research, Nanchang: university of Nanchang, 2015 ]. Puerarin can promote the expression of HK2 cells ABCG2, thereby promoting the excretion of uric acid [ zhanghong long, zhangying, laanguangfu, etc.. puerarin influences the expression of human renal proximal tubular epithelial cells ABCG 2. journal of chinese medicine in shanghai, 2016 (3): 74]. Puerarin can reduce the level of uric acid in serum of hyperuricemia patients [ Wangyong, myricetin, the influence and significance of puerarin on hyperuricemia; Nemongol traditional Chinese medicine, 2010, 29 (19): 9].
Lalang grass rhizome (Imperata cylindracea Beauv. var. major. C.E.Hubb) is dried rhizome of Cymbopogon citratus of Gramineae, has effects of cooling blood, stopping bleeding, clearing heat, and inducing diuresis, and can be used for treating hematemesis, hematuria, fever polydipsia, jaundice, edema oliguria, stranguria with heat, etc. Modern pharmacological research shows that the traditional Chinese medicine composition mainly has the effects of reducing blood sugar and blood fat, resisting oxidation and resisting inflammation. The cogongrass rhizome water decoction can relieve the mouse pinnacle swelling caused by xylene and relieve the rat hind toe swelling caused by carrageenan to exert the anti-inflammatory curative effect [ Yuxing, Houzongxian, Liu Ping, etc.. the cogongrass rhizome has the pharmacological action of anti-inflammation, Chinese clinical rehabilitation, 2006, 10 (43): 85-87]. The cogongrass rhizome polysaccharide can obviously improve the blood sugar regulation capacity of a diabetic mouse, and can obviously improve the blood lipid index [ red yu, Lichao, Yujian, and the like ] in the diabetic mouse, the cogongrass rhizome polysaccharide improves the research of the glycolipid metabolism of the mouse, the food science, 2012 and 33 (19): 302-305].
The invention selects cyclocarya paliurus, corn stigma, radix puerariae and rhizoma imperatae to carry out prescription, and utilizes the radix puerariae to reduce the generation of uric acid and promote the excretion of uric acid, thereby playing the anti-gout effect from the source; the corn stigma is utilized to realize the effect of treating gout and simultaneously generate the effect of reducing blood sugar, and simultaneously, hyperglycemia complications caused by gout are obviously improved; cyclocarya paliurus has a treatment effect on gout through antioxidant and anti-inflammatory drug effects; the cogongrass rhizome treats gout and hyperlipidemia complications caused by gout by resisting inflammation and reducing blood sugar.
The traditional Chinese medicine composition disclosed by the invention is simple in raw material components and simple and convenient in preparation process, can retain bioactive components of the components, and fully exerts the pharmacological action of the components in the composition. The traditional Chinese medicine composition can treat gout by resisting oxidation and inflammation, can reduce the generation of uric acid from the source and promote the excretion of uric acid to play the anti-gout effect, and can treat complications such as hyperglycemia, hyperlipidemia and the like caused by gout. Has the characteristics of safety and no toxic or side effect, and is suitable for long-term administration of gout patients.
Detailed Description
Example 1
A traditional Chinese medicine composition for treating gout comprises, by weight, 40 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of lalang grass rhizome.
The specific implementation steps are as follows:
a) weighing 40 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of rhizoma imperatae, placing the materials in an extraction tank, and adding distilled water which is 8 times of the total mass of the raw materials into the extraction tank to enable the distilled water to fully immerse the raw material mixture.
b) Decocting at 80-100 deg.C for 3 times, each for 1-2 hr, filtering the hot filtrate, and mixing the filtrates.
c) Concentrating the combined filtrate at 60 deg.C under reduced pressure to obtain soft extract with relative density of 1.20-1.30.
d) Drying the thick extract in a vacuum drying oven at 60 deg.C to obtain dry powder.
e) Packaging the dry powder.
Example 2
A traditional Chinese medicine composition for treating gout comprises, by weight, 60 parts of cyclocarya paliurus, 25 parts of corn stigma, 15 parts of radix puerariae and 15 parts of lalang grass rhizome.
The specific implementation steps are as follows:
a) weighing 60 parts of cyclocarya paliurus, 25 parts of corn stigma, 15 parts of radix puerariae and 15 parts of rhizoma imperatae, placing the materials in an extraction tank, and adding distilled water 9 times of the total mass of the raw materials into the extraction tank to enable the distilled water to fully immerse the raw material mixture.
b) Decocting at 80-100 deg.C for 3 times, each for 1-2 hr, filtering the hot filtrate, and mixing the filtrates.
c) Concentrating the combined filtrate at 60 deg.C under reduced pressure to obtain soft extract with relative density of 1.20-1.30.
d) Drying the thick extract in a vacuum drying oven at 60 deg.C to obtain dry powder.
e) Packaging the dry powder.
Example 3
A traditional Chinese medicine composition for treating gout comprises, by weight, 80 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of lalang grass rhizome.
The specific implementation steps are as follows:
a) weighing 80 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of rhizoma imperatae, placing the materials in an extraction tank, and adding distilled water which is 10 times of the total mass of the raw materials into the extraction tank to enable the distilled water to fully immerse the raw material mixture.
b) Decocting at 80-100 deg.C for 3 times, each for 1-2 hr, filtering the hot filtrate, and mixing the filtrates.
c) Concentrating the combined filtrate at 60 deg.C under reduced pressure to obtain soft extract with relative density of 1.20-1.30.
d) Drying the thick extract in a vacuum drying oven at 60 deg.C to obtain dry powder.
e) Packaging the dry powder.
Example 4 clinical effects of a Chinese medicinal composition for treating gout
Firstly, gout patients with clinically confirmed diagnosis are selected to eliminate gout false positive patients, so that the experimental result is more objective, real and credible.
Inclusion criteria for gout patients a screen of gout patients was performed in clinical trials with gout classification criteria determined by the American College of Rheumatology (ACR)/european antirheumatic union (EULAR) in 2015.
The gout classification diagnosis standard comprises 3 items and 8 items, the number of the items is 23, and gout can be diagnosed when the actual condition of a patient meets 8. The criteria comprehensively assessed the clinical characteristics of patients from clinical parameters (1-4 strips), laboratory parameters (5-6 strips) and imaging parameters (7-8 strips).
From 100 suspected gout patients who were clinically diagnosed, 90 patients were diagnosed as gout patients, 60 of which were the first acute gout attack patients, 16 of which were the recurrent patients of gout, and 14 of which were the chronic gout patients with complications of hyperglycemia and hyperlipidemia, using the above diagnostic criteria.
The composition extract was obtained according to the preparation recipe and process of example three. The composition is administered with 10 g/bag, and the dosage of the patient is 1 bag per time, and the composition is administered with boiled water in the morning and evening respectively for 30 days. The therapeutic effect is shown in table 1.
TABLE 1 therapeutic Effect of the compositions of the present invention
The treatment effect on gout patients is as follows:
as can be seen from table 1, the traditional Chinese medicine composition of the present invention has fast onset of therapeutic effect on patients with gout, especially patients with acute gout attack; the traditional Chinese medicine composition has the characteristic of high cure rate for various gout, particularly the cure rate of 100 percent for patients with chronic gout accompanied by hyperglycemia and hyperlipidemia complications, and no adverse reaction occurs to the patients in the treatment process. Therefore, the formula can be used for treating gout and has the characteristics of safety and no toxic or side effect.
Example 5
5.1 preparation of extract
The extract is obtained according to the formula and the process of the third embodiment, any mixture of the three traditional Chinese medicines and any mixture of the two traditional Chinese medicines in the formula are extracted according to the proportion and the process of the single traditional Chinese medicine in the third embodiment, and the extract of the single traditional Chinese medicine is extracted according to the extraction process in the third embodiment.
5.2 Experimental groups
Blank group, model group, cyclocarya paliurus group, puerariae group, imperata rhizome group, stigma Maydis group, cyclocarya paliurus group (cyclocarya paliurus + puerariae root, the same below), cyclocarya paliurus group (cyclocarya paliurus + imperata rhizome, the same below), chrysoidine group (cyclocarya paliurus + stigma Maydis, the same below), puerariae rhizome group (puerariae + rhizoma imperatae, the same below), puerariae jade group (puerariae + stigma Maydis, the same below), chrysoidine group (rhizoma imperatae + stigma Maydis, the same below), cyclocarya paliurus + puerariae + rhizoma imperatae, the same below), cyclocarya paliurus group (cyclocarya paliurus + rhizoma imperatae + stigma Maydis, the same below), cyclocarya paliurus + puerariae root + rhizoma imperatae + stigma Maydis, and four traditional Chinese medicines extracted respectively form extracts, in accordance with the example, the three-component, cyclocarya paliurus + rhizoma alismatis group (cyclocarya paliurus + rhizoma imperatae), and the four traditional Chinese medicines are extracted according to the proportion and the process of the three traditional Chinese medicines) and the positive medicine group.
5.3 prophylactic administration
SD rat, 180-220 g. Animals are bred adaptively for one week, and then preventive gavage administration is carried out (the dosage of the composition and the extract of a single traditional Chinese medicine is calculated according to the crude drug amount of 2g/kg of rats and the extraction rate of the composition and the single traditional Chinese medicine respectively, and the dosage of the positive medicine is calculated according to the clinical effective dosage of the positive medicine to guide the dosage of the rats. Blank group and model group are given with 0.5% CMC-Na blank solvent, administration group is respectively according to 500mg/kg of cyclocarya paliurus group, 700mg/kg of radix puerariae group, 420mg/kg of rhizoma imperatae group, 650mg/kg of corn stigma group, 580mg/kg of radix puerariae group, 490mg/kg of radix cyanin group, 600mg/kg of green jade group, 580mg/kg of radix puerariae group, 670mg/kg of radix puerariae group, 550mg/kg of white jade group, 660mg/kg of radix puerariae group, 640mg/kg of radix puerariae group, 535mg/kg of white jade group, 610mg/kg of radix puerariae group, 580mg/kg of white jade group, 600mg/kg of formula group, 0.3mg/kg of positive group is administered by stomach irrigation, and is continuously administered for 7 days.
5.4 sodium urate-induced acute gout model
On day 6 of dosing, rats were anesthetized after the gavage was completed. 0.2mL of 0.9% normal saline is injected into the ankle joint cavity of the blank group, and 0.2mL of sodium urate crystal with the injection concentration of 20mg/mL is injected into the ankle joint cavity of the other groups, so that an acute gout model is induced.
5.5 pharmacodynamic evaluation
After the gavage was completed on day 7 of the administration, the degree of swelling of the joints of the right hind limb of the rat 24 hours after the molding was determined, blood was taken from the orbit, and the serum was separated and the contents of IL-1 β and TNF- α in the serum were measured.
And (5) experimental results. See tables 2 and 3.
TABLE 2 degree of ankle swelling
Note: in comparison with the blank set, the results,**p is less than 0.01; in comparison to the model set,#p＜0.05，##p＜0.01
compared with the blank group, the ankle swelling of the animals in the model group is obviously increased (p is less than 0.01), which indicates that the acute gout model is successfully induced; compared with a model group, the single traditional Chinese medicine, any two-component combination of the single traditional Chinese medicine, any three-component combination of the single traditional Chinese medicine and extract combination of four traditional Chinese medicines of each formula can reduce the ankle swelling degree (p is less than 0.05) of a rat, the formula group can obviously reduce the ankle swelling degree (p is less than 0.01), the formula can relieve the ankle swelling caused by the attack of acute gout of animals, the effect of the formula is better than that of other administration groups, and the purpose of treating gout can be achieved through synergistic effect of the components of the formula; compared with a model group, the positive medicine group can show the swelling degree of the ankle joint (p is less than 0.01), and the explanatory medicine can play a good role in treating acute gout. Compared with the positive medicine group, the prescription group has no significant difference, which shows that the prescription and the positive medicine have equivalent effects on treating acute gout.
TABLE 3 rat serum IL-1 β and TNF- α levels
Note: in comparison with the blank set, the results,**p is less than 0.01; in comparison to the model set,##p＜0.01，#p＜0.05
compared with a blank group, IL-1 β and TNF- α in serum of a model group are obviously increased (p is less than 0.01), which indicates that an acute gout model induced by sodium urate is successful, compared with the model group, the contents of IL-1 β and TNF- α in animal serum of a single medicine, any two traditional Chinese medicine combination, three traditional Chinese medicine combination and four traditional Chinese medicine extract group are obviously reduced (p is less than 0.05 and p is less than 0.05), the contents of IL-1 β and TNF- α in animal serum of the formula group are obviously reduced (p is less than 0.01 and p is less than 0.01) and the contents of IL-1 β and TNF- α in animal serum of the formula are obviously reduced (p is less than 0.01 and p is less than 0.01) to indicate that the formula can fully play a synergistic effect to treat gout, compared with the model group, the contents of IL- β and TNF- α in animal serum of the positive medicine can be obviously reduced (p is less than 0.01 and p is less than 0.01) to indicate that the positive gout can be treated, and compared with the acute gout treatment group, the acute gout group and the acute gout treatment group has no obvious effect.
Claims (4)
1. A traditional Chinese medicine composition for treating gout is characterized in that: the composition comprises the following raw materials in parts by weight:
40-80 parts of cyclocarya paliurus, 10-40 parts of corn stigma, 5-30 parts of kudzu root and 5-30 parts of lalang grass rhizome.
2. The traditional Chinese medicine composition for treating gout according to claim 1, wherein: the composition comprises the following raw materials in parts by weight: 80 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of rhizoma imperatae.
3. The method for preparing the traditional Chinese medicine composition for treating gout according to claim 1 or 2, which is characterized by comprising the following steps: mixing the raw materials at a certain ratio, decocting, concentrating, drying, pulverizing, sieving and packaging.
4. The preparation method of the traditional Chinese medicine composition for treating gout according to claim 3, wherein the preparation method comprises the following steps: the method comprises the following specific steps:
a) adding 8-10 times of distilled water according to the total mass of the mixed raw materials;
b) decocting the mixture at 80-100 deg.C for 1-2 hr for 2-3 times;
c) concentrating the obtained decoction under reduced pressure to obtain soft extract with relative density of 1.20-1.30;
d) drying the obtained thick extract at 60-80 deg.C to obtain dry powder;
e) packaging the dry powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810957243.2A CN110833595B (en) | 2018-08-17 | 2018-08-17 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810957243.2A CN110833595B (en) | 2018-08-17 | 2018-08-17 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110833595A true CN110833595A (en) | 2020-02-25 |
| CN110833595B CN110833595B (en) | 2021-07-20 |
Family
ID=69573950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810957243.2A Active CN110833595B (en) | 2018-08-17 | 2018-08-17 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110833595B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112807390A (en) * | 2021-01-22 | 2021-05-18 | 梁俊雄 | Gout tea bag and preparation method and application thereof |
| CN114098089A (en) * | 2021-10-22 | 2022-03-01 | 朗姿赛尔生物科技（广州）有限公司 | Composite peptide composition and composite peptide seasoning tea |
| CN114246933A (en) * | 2021-12-01 | 2022-03-29 | 广州宏韵医药科技股份有限公司 | Composition and food for reducing uric acid, and preparation method and application thereof |
| CN115887587A (en) * | 2022-12-20 | 2023-04-04 | 贵州米畴亨生物科技有限公司 | Mountain grass tea capable of promoting urination and reducing uric acid |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940282A (en) * | 2015-06-05 | 2015-09-30 | 百花医花集团股份有限公司 | Cyclocarya paliurus preparation and preparation method thereof |
| CN107087697A (en) * | 2017-03-29 | 2017-08-25 | 广西凌云县盘古生态产业发展有限公司 | It is a kind of can anti-trioxypurine sleeping type cyclocarya paliurus tea and preparation method thereof |
-
2018
- 2018-08-17 CN CN201810957243.2A patent/CN110833595B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940282A (en) * | 2015-06-05 | 2015-09-30 | 百花医花集团股份有限公司 | Cyclocarya paliurus preparation and preparation method thereof |
| CN107087697A (en) * | 2017-03-29 | 2017-08-25 | 广西凌云县盘古生态产业发展有限公司 | It is a kind of can anti-trioxypurine sleeping type cyclocarya paliurus tea and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| 刘丽娟等: "葛根治疗痛风的临床疗效", 《吉林大学学报（医学版）》 * |
| 律广富等: "玉米须总黄酮提取物对痛风性肾病大鼠肾脏尿酸排泄的影响", 《中成药》 * |
| 无: "降糖降压降血脂防痛风的青钱柳", 《HTTPS://WWW.JIANKE.COM/XNXGPD/5093270.HTML》 * |
| 杨长春: "《痛风这样做 止痛降尿酸》", 31 July 2018, 江苏凤凰科学技术出版社 * |
| 林贺等: "玉米须黄酮提取物对痛风性关节炎大鼠的影响", 《现代食品科技》 * |
| 马越等: "葛根提取物抗痛风性关节炎作用及机制初探", 《中药新药与临床药理》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112807390A (en) * | 2021-01-22 | 2021-05-18 | 梁俊雄 | Gout tea bag and preparation method and application thereof |
| CN114098089A (en) * | 2021-10-22 | 2022-03-01 | 朗姿赛尔生物科技（广州）有限公司 | Composite peptide composition and composite peptide seasoning tea |
| CN114098089B (en) * | 2021-10-22 | 2023-06-23 | 朗姿赛尔生物科技（广州）有限公司 | Composite peptide composition and composite peptide seasoning tea |
| CN114246933A (en) * | 2021-12-01 | 2022-03-29 | 广州宏韵医药科技股份有限公司 | Composition and food for reducing uric acid, and preparation method and application thereof |
| CN115887587A (en) * | 2022-12-20 | 2023-04-04 | 贵州米畴亨生物科技有限公司 | Mountain grass tea capable of promoting urination and reducing uric acid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110833595B (en) | 2021-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110833595B (en) | Traditional Chinese medicine composition for treating gout and preparation method thereof | |
| CN1964730B (en) | Herbal compositions for prevention and treatment rheumatic and inflammatory diseases and method of preparing the same | |
| Tao et al. | Regulation effects on abnormal glucose and lipid metabolism of TZQ-F, a new kind of Traditional Chinese Medicine | |
| CN100488552C (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN104172159A (en) | Composition with auxiliary protection effect on alcoholic liver injury and preparation method thereof | |
| CN105920067A (en) | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN101879297B (en) | Prostate recovery capsules of Chinese medicinal compound preparation, preparation process and application thereof | |
| CN1622819A (en) | An anti-rheumatism medicament and preparation method thereof | |
| JP4516958B2 (en) | Anti-diabetic composition | |
| KR20040060808A (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| CN106798854B (en) | Phyllanthus emblica leaf and preparation method thereof | |
| CN103100028A (en) | Soft capsule favorable for reducing alcoholic liver injury and preparation method thereof | |
| CN102688263B (en) | Geranium strictipes effective part preparation and medical use of geranium strictipes for preventing and curing colonitis | |
| CN101199652B (en) | Medicament for treating acute, subacute eczema and preparing method thereof | |
| CN103705578A (en) | Traditional Chinese medicine preparation with functions of reducing blood fat and inhibiting blood glucose increase and preparation method thereof | |
| WO2013138964A1 (en) | Application of iso-daphnetin compound in preparation of anti-diabetic medicines | |
| KR100315001B1 (en) | Herbal Medicine for the Treatment of Diabetes Mellitus Containing Enteric Bellflower Extract | |
| CN102755568B (en) | Health-care product for assisting in decreasing blood sugar and preparation method thereof | |
| CN101167887A (en) | Orally-administered matrimony vine single preparation traditional Chinese medicine for treating diabetes and preparation method thereof | |
| WO2006015522A1 (en) | A capsule for regulation of blood pressure and hyperlipemia and prevention and treatment of cardiovascular and cerebrovascular diseases | |
| CN114767760B (en) | A composition with liver protecting effect | |
| El-Hashash | Co-therapeutic effects of metformin and Sidr fruits and leaves in experimental diabetic rats | |
| CN118542906B (en) | A Chinese medicinal composition for improving pulmonary fibrosis and pulmonary nodule, and its preparation method | |
| CN107334988B (en) | Traditional Chinese medicine composition for treating pulmonary abscess |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |